Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07 2021 - 7:00AM
Business Wire
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage
precision medicine company developing innovative treatments for
genetically defined age-related macular degeneration (AMD), today
announced that Jason Meyeburg, Chief Executive Officer of Gemini
Therapeutics, is scheduled to participate virtually in the H.C.
Wainwright 23rd Annual Global Investment Conference. The
presentation will be available on-demand starting at 7 AM ET on
Monday, September 13, 2021.
A webcast of the event will be available on the "Events &
Presentations" page on the Company's website. A replay of the
webcast will be archived on the Company's website for 30 days
following the presentation.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine
company developing novel therapeutic compounds to treat genetically
defined age-related macular degeneration (AMD). Gemini’s lead
candidate, GEM103, is a recombinant form of human complement factor
H protein (CFH) and is designed to address both complement
hyperactivity and restore retinal health in patients with AMD.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a
CFH risk variant and a Phase 1/2a study in patients with
neovascular age-related macular degeneration with or at risk for
macular atrophy. Gemini has generated a rich pipeline including
recombinant proteins, gene therapies, and monoclonal antibodies and
is advancing a potentiating antibody for CFH, GEM307, into clinical
development for treatment of systemic diseases.
For more information, visit www.geminitherapeutics.com.
Availability of Other Information About Gemini
Therapeutics
Investors and others should note that we communicate with our
investors and the public using our website
(www.geminitherapeutics.com), the investor relations website
(https://investors.geminitherapeutics.com/), and on social media
(Twitter and LinkedIn), including but not limited to investor
presentations and investor fact sheets, U.S. Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Gemini posts on these
channels and websites could be deemed to be material information.
As a result, Gemini encourages investors, the media, and others
interested in Gemini to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time to
time on Gemini’s investor relations website and may include
additional social media channels. The contents of Gemini’s website
or these channels, or any other website that may be accessed from
its website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210907005047/en/
Gemini Investor: Argot Partners Sherri Spear 212-600-1902
gemini@argotpartners.com Gemini Media: Argot Partners Joshua
Mansbach 212-600-1902 gemini@argotpartners.com
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024